The Oncology Institute Inc. logo

The Oncology Institute Inc. (TOI)

Market Closed
27 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
5. 19
+0.21
+4.2169%
$
528.91M Market Cap
- P/E Ratio
- Div Yield
1.43M Volume
-0.36 Eps
$ 4.98
Previous Close
Add Transaction
Day Range
5.03 5.32
Year Range
2.32 6.67
Want to track TOI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TOI closed today higher at $5.19, an increase of 4.2169% from yesterday's close, completing a monthly decrease of -3.1716% or -$0.17. Over the past 12 months, TOI stock gained 45.7865%.
TOI is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0.0933%. On average, the company has surpassed earnings expectations by 0.0978%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

TOI Chart

People also search for

UFP Technologies Inc.
$ 248.63
+4.8187%
Pavella Therapeutics Inc.
$ 141.77
+2.7244%
Viridian Therapeutics Inc.
$ 19.7
+2.2314%
Forte Biosciences, Inc.
$ 76.5
+39.6495%
MoonLake Immunotherapeutics
$ 19.88
+4.5216%
Best Cheap Stocks Under $10 to Buy Now in July

Best Cheap Stocks Under $10 to Buy Now in July

One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.

Zacks | 2 weeks ago
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?

The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?

The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 4 weeks ago
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%

How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%

The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 month ago

The Oncology Institute Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
CE
Curtis Ellergodt Rothschild Investment LLC
1 $3.56 $5.43 $1.87 52.53%
BG
Bart Gancher Intech Investment Management LLC
22,482 $50,943.3 $123,651 $72,707.7 142.72%
Daren Blonski
Daren Blonski Fermata Advisors LLC
12,800 $65,280 $69,568 $4,288 6.57%
Joseph Castro
Joseph Castro Nuveen LLC
95,264 $214,255.35 $523,952 $309,696.65 144.55%
MPM
Mark P. Mennitt CenterBook Partners LP
1.57M $5.5M $8.67M $3.18M 57.8%

The Oncology Institute Inc. (TOI) FAQ

What is the stock price today?

The current price is $5.19.

On which exchange is it traded?

The Oncology Institute Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is TOI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 528.91M.

Has The Oncology Institute Inc. ever had a stock split?

No, there has never been a stock split.

The Oncology Institute Inc. Profile

Health Care Providers & Services Industry
Healthcare Sector
Daniel Virnich CEO
NASDAQ (CM) Exchange
68236X100 CUSIP
US Country
641 Employees
- Last Dividend
- Last Split
15 Nov 2021 IPO Date

Overview

The Oncology Institute, Inc. is an American oncology company specializing in a wide range of oncology services. Founded in 2007 and headquartered in Cerritos, California, the institute is dedicated to providing comprehensive care for adult and senior cancer patients. With 67 clinic locations across the United States, it offers a broad spectrum of integrated services aimed at the management and treatment of cancer. The company's approach to cancer care includes a combination of medical oncology services, innovative therapies, and patient support programs designed to address the individual needs of each patient.

Products and Services

  • Physician Services: Consists of consultations, diagnosis, and treatment plans developed by experienced oncologists. The Oncology Institute prides itself on employing skilled physicians who are dedicated to providing personalized and comprehensive care to each patient.
  • In-house Infusion and Dispensary: Offers convenient on-site access to chemotherapy and other medication infusions. This service allows patients to receive their treatment in a comfortable and controlled environment, supervised by the institute's medical professionals.
  • Clinical Trial Services: Participates in and manages clinical trials aimed at exploring new cancer treatments and therapies. By providing access to cutting-edge clinical trials, the Oncology Institute plays a crucial role in advancing cancer research and offering hope for innovative treatment options to its patients.
  • Radiation: Includes advanced radiation therapy options as part of a comprehensive cancer treatment plan. Radiation therapy is used to target and destroy cancer cells, and is often combined with other treatments for optimal outcomes.
  • Outpatient Stem Cell Transplants and Transfusions Programs: Provides advanced treatments like stem cell transplants and blood transfusions on an outpatient basis, reducing the need for hospital stays and allowing patients to recover in the comfort of their own homes.
  • Patient Support: Focuses on the well-being of patients beyond clinical treatment, offering services that include palliative care programs designed to help manage symptoms and improve quality of life. The company recognizes the importance of holistic care and strives to support patients and their families throughout the cancer journey.

Contact Information

Address: 18000 Studebaker Road
Phone: 213 760 1328